(Q37710134)

22 August 2017

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma (English)

1 reference

22 August 2017

2

Masatoshi Kudo

1 reference

22 August 2017

12

Hiromitsu Kumada

1 reference

22 August 2017

1

Kenji Ikeda

1 reference

22 August 2017

Seiji Kawazoe

3

1 reference

22 August 2017

Yukio Osaki

4

1 reference

22 August 2017

Masafumi Ikeda

5

1 reference

22 August 2017

Takuji Okusaka

6

1 reference

22 August 2017

Toshiyuki Tamai

7

1 reference

22 August 2017

Takuya Suzuki

8

1 reference

22 August 2017

Takashi Hisai

9

1 reference

22 August 2017

Seiichi Hayato

10

1 reference

22 August 2017

Kiwamu Okita

11

1 reference

22 August 2017

4 October 2016

1 reference

Journal of Gastroenterology

22 August 2017

1 reference

22 August 2017

52

1 reference

22 August 2017

4

1 reference

22 August 2017

512-519

1 reference

Creative Commons Attribution 4.0 International

22 August 2017

start time

4 October 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Sorafenib in advanced hepatocellular carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Design and endpoints of clinical trials in hepatocellular carcinoma.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

A validated LC-MS/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5357473

Management of hepatic encephalopathy

1 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00535-016-1263-4

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27704266

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27704266

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00535-016-1263-4

1 reference

22 August 2017

1 reference

22 August 2017

PubMed publication ID

27704266

1 reference